An Extension Study to Evaluate Safety and Efficacy of Atumelnant in Participants With Congenital Adrenal Hyperplasia
Clinical trial NCT06712823 · RECRUITING
Trial details
- NCT number
- NCT06712823
- Sponsor
- Crinetics Pharmaceuticals Inc.
- Status
- RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2025-02-25
- Primary completion
- 2029-07-01
- Enrollment
- 200
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.